arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

TriSalus Life Sciences, Inc.

TLSI
$4.99 ▼ -0.91 (-15.42%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
24 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
54
Health
Fair
Neutral
auto_awesome

Analytical Summary

TriSalus Life Sciences, Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $290.9M
Dividend Yield
Revenue Growth 1.7%
Op. Margin -86.0%
ROIC -24.8%
FCF / Share $-0.18
Trailing P/E
Price / Book 46.8x
FCF Yield
Debt / Equity 5.05
info Valuation on last close. End-of-day price, Sep 23, 2026.

24-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$11.41M
↑ +1.7%
Net Income Profit after all expenses
$1.54M
— 0.0%
Operating Margin Operating profit as % of sales
-86.0%
↑ +9.0% 4th
FCF / Share Free cash flow per share
$-0.18
↓ -36.3%
Long-Term Debt Long-term obligations
$33.06M
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
99
Financial Health
67
Cash Quality
39

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 24 quarters